Testing effectiveness (Phase 2)Active Not RecruitingNCT02962063
What this trial is testing
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
Who this might be right for
Esophageal AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Memorial Sloan Kettering Cancer Center 64